Mutations described in children and adolescents with HSTCL and existing targeted therapies
| Mutation . | Therapy class . | Targeted therapy . |
|---|---|---|
| SETD2, INO80, TET2, TET3 | Histone deacetylase inhibitor | Vorinostat and romidepsin |
| SMARCA2, ARID1B | Hypomethylating agent | Decitabine and azacitidine |
| STAT3, STAT5B | JAK inhibitor | Ruxolitinib and fedratinib |
| PIK3CD | PI3K inhibitor | Idelalisib, copanlisib, duvelisib, and alpelisib |
| SYK | SYK inhibitor | Fostamatinib |
| FLT3 | FLT3 inhibitor | Midostaurin, quizartinib, and gilteritinib |
| Mutation . | Therapy class . | Targeted therapy . |
|---|---|---|
| SETD2, INO80, TET2, TET3 | Histone deacetylase inhibitor | Vorinostat and romidepsin |
| SMARCA2, ARID1B | Hypomethylating agent | Decitabine and azacitidine |
| STAT3, STAT5B | JAK inhibitor | Ruxolitinib and fedratinib |
| PIK3CD | PI3K inhibitor | Idelalisib, copanlisib, duvelisib, and alpelisib |
| SYK | SYK inhibitor | Fostamatinib |
| FLT3 | FLT3 inhibitor | Midostaurin, quizartinib, and gilteritinib |